Muscle Loss on GLP-1s: How Much Is Normal, and What Actually Prevents It
The muscle loss concern around GLP-1 drugs is real but frequently overstated. DEXA data from major trials shows that 25–40% of weight lost on GLP-1 agonists is lean mass — but that ratio is comparable to what happens with any form of significant weight loss, including diet alone.1,2
What the Trial Data Actually Shows
In STEP-1 (semaglutide), DEXA body composition substudy data showed lean mass decreased by approximately 9.7% while fat mass fell by approximately 19.3%. Critically, the proportion of body weight that was lean mass actually increased by about 3 percentage points — meaning patients became proportionally leaner even though absolute lean mass decreased.1,3
A 2026 real-world cohort of 486 patients showed skeletal muscle dropped about 5% while fat dropped roughly 18%.6
A Medscape analysis in May 2026 compared lean mass loss in GLP-1 users versus lifestyle-only weight loss. Using preset benchmarks (>25% of weight lost as fat-free mass via DEXA), 68% of GLP-1 users exceeded the threshold — but so did 50% of the lifestyle-only group. The conclusion: muscle loss is a feature of weight loss itself, not unique to GLP-1 drugs.4
What Actually Prevents Lean Mass Loss
Two interventions have consistent evidence:
1. Resistance Training
The European Association for the Study of Obesity recommends resistance training specifically (not just aerobic exercise) to attenuate lean body mass loss during weight reduction. Multiple systematic reviews confirm that resistance exercise effectively counteracts potential adverse effects of weight loss on lean mass and reduces the risk of sarcopenia.3
2. Adequate Protein Intake
Current evidence supports protein intake of 1.2–1.6g per kg of body weight per day during GLP-1 therapy — higher than the general 0.8g/kg RDA. This is particularly challenging because GLP-1 drugs suppress appetite, making it difficult to consume enough protein. Protein-first meal planning, protein supplementation, and caloric-density awareness are practical strategies.
The Pipeline Response
Drug developers are building solutions into their next-generation compounds:
| Approach | Drug/Combination | Status | Lean Mass Impact |
|---|---|---|---|
| Myostatin inhibition | Bimagrumab + semaglutide | Phase 2 | ~90% of weight loss was fat in combination |
| GLP-1/glucagon dual agonist | Pemvidutide | Phase 2b | Better lean mass retention by design |
| Selective androgen receptor modulator | Under investigation | Preclinical | Theoretical muscle preservation |
The bottom line: muscle loss during GLP-1 therapy is real, proportional to total weight loss, comparable to other weight-loss methods, and largely preventable with resistance training and adequate protein. It is not a reason to avoid GLP-1 treatment, especially given the overwhelming cardiovascular, metabolic, and mortality benefits documented in SELECT and other trials.
SOURCES
- Wilding JPH, et al. STEP 1: semaglutide body composition substudy. NEJM. 2021;384:989-1002.
- Jastreboff AM, et al. SURMOUNT-1 tirzepatide body composition data. NEJM. 2022;387:205-216.
- Frontiers in Clinical Diabetes. GLP-1 agonists and exercise: lean mass preservation. 2025.
- Medscape. No Need to Worry About GLP-1-Induced Muscle Loss. May 2026.
- AHA Circulation. Muscle Mass and GLP-1 Receptor Agonists: Adaptive or Maladaptive Response. 2025.
- 2026 cohort study: skeletal muscle dropped ~5% while fat dropped ~18% in 486 patients.